Literature DB >> 11784313

A catalytically inactive beta 1,4-N-acetylglucosaminyltransferase III (GnT-III) behaves as a dominant negative GnT-III inhibitor.

Hideyuki Ihara1, Yoshitaka Ikeda, Souichi Koyota, Takeshi Endo, Koichi Honke, Naoyuki Taniguchi.   

Abstract

beta 1,4-N-Acetylglucosaminyltransferase III (GnT-III) plays a regulatory role in the biosynthesis of N-glycans, and it has been suggested that its product, a bisecting GlcNAc, is involved in a variety of biological events as well as in regulating the biosynthesis of the oligosaccharides. In this study, it was found, on the basis of sequence homology, that GnT-III contains a small region that is significantly homologous to both snail beta 1,4GlcNAc transferase and beta1,4Gal transferase-1. Subsequent mutational analysis demonstrated an absolute requirement for two conserved Asp residues (Asp321 and Asp323), which are located in the most homologous region of rat GnT-III, for enzymatic activity. The overexpression of Asp323-substituted, catalytically inactive GnT-III in Huh6 cells led to the suppression of the activity of endogenous GnT-III, but no significant decrease in its expression, and led to a specific inhibition of the formation of bisected sugar chains, as shown by structural analysis of the total N-glycans from the cells. These findings indicate that the mutant serves a dominant negative effect on a specific step in N-glycan biosynthesis. This type of 'dominant negative glycosyltransferase', identified has potential value as a powerful tool for defining the precise biological roles of the bisecting GlcNAc structure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11784313     DOI: 10.1046/j.0014-2956.2001.02640.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  4 in total

1.  Bisecting GlcNAc Is a General Suppressor of Terminal Modification of N-glycan.

Authors:  Miyako Nakano; Sushil K Mishra; Yuko Tokoro; Keiko Sato; Kazuki Nakajima; Yoshiki Yamaguchi; Naoyuki Taniguchi; Yasuhiko Kizuka
Journal:  Mol Cell Proteomics       Date:  2019-08-02       Impact factor: 5.911

2.  Dynamic control of oligosaccharide modification in the mammary gland: linking recombinant human erythropoietin functional analysis of transgenic mouse milk-derived hEPO.

Authors:  Deug-Nam Kwon; Hyuk Song; Jong-Yi Park; So-Young Lee; Seong-Keon Cho; Sung-Jo Kang; Joung Soon Jang; Han Geuk Seo; Jin-Hoi Kim
Journal:  Transgenic Res       Date:  2006-02       Impact factor: 2.788

3.  An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer's disease.

Authors:  Yasuhiko Kizuka; Shinobu Kitazume; Reiko Fujinawa; Takashi Saito; Nobuhisa Iwata; Takaomi C Saido; Miyako Nakano; Yoshiki Yamaguchi; Yasuhiro Hashimoto; Matthias Staufenbiel; Hiroyuki Hatsuta; Shigeo Murayama; Hiroshi Manya; Tamao Endo; Naoyuki Taniguchi
Journal:  EMBO Mol Med       Date:  2015-02       Impact factor: 12.137

4.  Neofunctionalization of the Sec1 α1,2fucosyltransferase paralogue in leporids contributes to glycan polymorphism and resistance to rabbit hemorrhagic disease virus.

Authors:  Kristina Nyström; Joana Abrantes; Ana Margarida Lopes; Béatrice Le Moullac-Vaidye; Stéphane Marchandeau; Jézabel Rocher; Nathalie Ruvoën-Clouet; Pedro J Esteves; Jacques Le Pendu
Journal:  PLoS Pathog       Date:  2015-04-15       Impact factor: 6.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.